Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on August 11, 2009, at a price of £11.81 per share through the Company's Share Reward Plan. Each individual acquired 10 shares via a personal contribution (partnership element) and 10 shares via a company contribution (matching element). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: August 11, 2009.
- Share Price: £11.81 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas.
- Volume: Each participant acquired a total of 20 shares (10 personal, 10 company match).
- Notification Date: August 12, 2009.